Smaller Potential of the Personal | GenomeWeb

Personalized medicine of the "the right drug for the right patient at the right time" ethos may help patients, but Forbes' Henry Miller writes that it might not be right for drug companies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.